<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36992322</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>23</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">614</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v15030614</ELocationID><Abstract><AbstractText>We present the case of a 76-year-old male patient persistently infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the setting of a stage IIIC cutaneous melanoma and non-Hodgkin's lymphoma (NHL). Due to the persistent coronavirus disease 19 (COVID-19), all cancer treatments were discontinued. Because of the worsening of his clinical state and the persistence of SARS-CoV-2 positivity for more than six months, the patient was treated with sotrovimab, which was ineffective due to resistance mutations acquired during that time. In order to resume cancer treatment and make the patient free from SARS-CoV-2, an in vitro screening of Evusheld monoclonal antibodies (tixagevumab-cilgavimab) against the viral strains isolated from the subject was performed. The promising results obtained during in vitro testing led to the authorization of the off-label use of Evusheld, which made the patient negative for SARS-CoV-2, thus, allowing him to resume his cancer treatment. This study highlights the Evusheld monoclonal antibodies' efficacy, not only in prevention but also in successful therapy against prolonged COVID-19. Therefore, testing neutralizing monoclonal antibodies in vitro against SARS-CoV-2 mutants directly isolated from patients could provide useful information for the treatment of people affected by long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cusi</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0001-8869-8164</Identifier><AffiliationInfo><Affiliation>Virology Unit, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Virology Unit, Department of Medical Biotechnolopgies, Santa Maria Alle Scotte University Hospital, V.le Bracci 16, 53100 Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Giacomo</LastName><ForeName>Anna Maria</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-9315-2158</Identifier><AffiliationInfo><Affiliation>Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Medical Sciences, Surgical and Neuroscience, 53100 Siena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Italian Network for Tumor Bio-Immunotherapy Foundation Onlus, 53100 Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anichini</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Virology Unit, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gori Savellini</LastName><ForeName>Gianni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2287-9258</Identifier><AffiliationInfo><Affiliation>Virology Unit, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terrosi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Virology Unit, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandolfo</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2174-0713</Identifier><AffiliationInfo><Affiliation>Virology Unit, Department of Medical Biotechnolopgies, Santa Maria Alle Scotte University Hospital, V.le Bracci 16, 53100 Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maio</LastName><ForeName>Michele</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0323-6321</Identifier><AffiliationInfo><Affiliation>Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Medical Sciences, Surgical and Neuroscience, 53100 Siena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Italian Network for Tumor Bio-Immunotherapy Foundation Onlus, 53100 Siena, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="Y">Melanoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="Y">Skin Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">post-exposure treatment</Keyword><Keyword MajorTopicYN="N">resistance</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36992322</ArticleId><ArticleId IdType="pmc">PMC10052532</ArticleId><ArticleId IdType="doi">10.3390/v15030614</ArticleId><ArticleId IdType="pii">v15030614</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou Z., Zhu Y., Chu M. Role of COVID-19 Vaccines in SARS-CoV-2 Variants. Front. Immunol. 2022;13:2273. doi: 10.3389/fimmu.2022.898192.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.898192</ArticleId><ArticleId IdType="pmc">PMC9165056</ArticleId><ArticleId IdType="pubmed">35669787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bin Lee A.R.Y., Wong S.Y., Chai L.Y.A., Lee S.C., Lee M.X., Muthiah M.D., Tay S.H., Teo C.B., Tan B.K.J., Chan Y.H., et al. Efficacy of COVID-19 vaccines in immunocompromised patients: Systematic review and meta-analysis. BMJ. 2022;376:e068632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8889026</ArticleId><ArticleId IdType="pubmed">35236664</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherer E.M., Babiker A., Adelman M.W., Allman B., Key A., Kleinhenz J.M., Piantadosi A. SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients. N. Engl. J. Med. 2022;386:2436&#x2013;2438. doi: 10.1056/NEJMc2202861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2202861</ArticleId><ArticleId IdType="pmc">PMC9202319</ArticleId><ArticleId IdType="pubmed">35675197</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnleitner S.T., Prelog M., Sonnleitner S., Hinterbichler E., Halbfurter H., Kopecky D.B.C., Walder G. Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host. Nat. Commun. 2022;13:2560. doi: 10.1038/s41467-022-30163-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30163-4</ArticleId><ArticleId IdType="pmc">PMC9090742</ArticleId><ArticleId IdType="pubmed">35538074</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey L., Beyrer C., Cohen M.S., Michael N.L., Bedford T., Rolland M. SARS-CoV-2 Variants in Patients with Immunosuppression. N. Engl. J. Med. 2021;385:562&#x2013;566. doi: 10.1056/NEJMsb2104756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsb2104756</ArticleId><ArticleId IdType="pmc">PMC8494465</ArticleId><ArticleId IdType="pubmed">34347959</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention, Pre-Exposure Prophylaxis with EVUSHELD.  [(accessed on 19 October 2022)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/pre-exposure-prophylaxis.html.</Citation></Reference><Reference><Citation>Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 1938;27:493&#x2013;497. doi: 10.1093/oxfordjournals.aje.a118408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a118408</ArticleId></ArticleIdList></Reference><Reference><Citation>Anichini G., Terrosi C., Gandolfo C., GoriSavellini G., Fabrizi S., Miceli G.B., Franchi F., Cusi M.G. Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees. Vaccines. 2022;10:808. doi: 10.3390/vaccines10050808.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050808</ArticleId><ArticleId IdType="pmc">PMC9144393</ArticleId><ArticleId IdType="pubmed">35632563</ArticleId></ArticleIdList></Reference><Reference><Citation>Anichini G., Terrosi C., Gandolfo C., GoriSavellini G., Fabrizi S., Miceli G.B., Cusi M.G. SARS-CoV-2 Antibody Response in Persons with Past Natural Infection. N. Engl. J. Med. 2021;385:90&#x2013;92. doi: 10.1056/NEJMc2103825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2103825</ArticleId><ArticleId IdType="pmc">PMC8063888</ArticleId><ArticleId IdType="pubmed">33852796</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto D., Park Y.J., Beltramello M., Walls A.C., Tortorici M.A., Bianchi S., Corti D. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290&#x2013;295. doi: 10.1038/s41586-020-2349-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2349-y</ArticleId><ArticleId IdType="pubmed">32422645</ArticleId></ArticleIdList></Reference><Reference><Citation>Destras G., Bal A., Simon B., Lina B., Josset L. Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients. Lancet Microbe. 2022;3:e559. doi: 10.1016/S2666-5247(22)00120-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00120-3</ArticleId><ArticleId IdType="pmc">PMC9142137</ArticleId><ArticleId IdType="pubmed">35636438</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockett R., Basile K., Maddocks S., Fong W., Agius J.E., Johnson-Mackinnon J., Sintchenko V. Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use. N. Engl. J. Med. 2022;386:1477&#x2013;1479. doi: 10.1056/NEJMc2120219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2120219</ArticleId><ArticleId IdType="pmc">PMC8929376</ArticleId><ArticleId IdType="pubmed">35263515</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra T., Dalavi R., Joshi G., Kumar A., Pandey P., Shukla S., Chande A. SARS-CoV-2 spike E156G/&#x394;157-158 mutations contribute to increased infectivity and immune escape. Life Sci. Alliance. 2022;5:e202201415. doi: 10.26508/lsa.202201415.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202201415</ArticleId><ArticleId IdType="pmc">PMC8927725</ArticleId><ArticleId IdType="pubmed">35296517</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy K.R., Rennick L.J., Nambulli S., Robinson-McCarthy L.R., Bain W.G., Haidar G., Duprex W.P. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science. 2021;371:1139&#x2013;1142. doi: 10.1126/science.abf6950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf6950</ArticleId><ArticleId IdType="pmc">PMC7971772</ArticleId><ArticleId IdType="pubmed">33536258</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeer A., Iqra I., Mohammad A., Sadaf S., Muhammad M., Arif M. The Comparison of Mutational Progression in SARS-CoV-2: A Short Updated Overview. J. Mol. Pathol. 2022;3:201&#x2013;218.</Citation></Reference><Reference><Citation>Touret F., Baronti C., Bouzidi H.S., de Lamballerie X. In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate. Sci. Rep. 2022;12:4683. doi: 10.1038/s41598-022-08559-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-08559-5</ArticleId><ArticleId IdType="pmc">PMC8931583</ArticleId><ArticleId IdType="pubmed">35304531</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin M.J., Ustianowski A., De Wit S., Launay O., Avila M., Templeton A., Eetsser M.T. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of COVID-19. N. Engl. J. Med. 2022;386:2188&#x2013;2200. doi: 10.1056/NEJMoa2116620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116620</ArticleId><ArticleId IdType="pmc">PMC9069994</ArticleId><ArticleId IdType="pubmed">35443106</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.V., Jayadevan R., Sashidharan S. Long COVID: An overview. Diabetes Metab. Syndr. 2021;15:869&#x2013;875. doi: 10.1016/j.dsx.2021.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y., Qiu X., Wang C., Zhao J., Jiang X., Niu W., Zhang F. Cancer associates with risk and severe events of COVID-19: A systematic review and meta-analysis. Int. J. Cancer. 2021;148:363&#x2013;374. doi: 10.1002/ijc.33213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.33213</ArticleId><ArticleId IdType="pmc">PMC7404763</ArticleId><ArticleId IdType="pubmed">32683687</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., P&#xe9;rez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Zaks T., COVE Study Group Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403&#x2013;416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran S., Truong T.H., Narendran A. Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis. Eur. J. Cancer. 2021;159:259&#x2013;274. doi: 10.1016/j.ejca.2021.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2021.10.013</ArticleId><ArticleId IdType="pmc">PMC8542448</ArticleId><ArticleId IdType="pubmed">34798454</ArticleId></ArticleIdList></Reference><Reference><Citation>Fendler A., de Vries E.G.E., GeurtsvanKessel C.H., Haanen J.B., W&#xf6;rmann B., Turajlic S., von Lilienfeld-Toal M. COVID-19 vaccines in patients with cancer: Immunogenicity, efficacy and safety. Nat. Rev. Clin. Oncol. 2022;19:385&#x2013;401. doi: 10.1038/s41571-022-00610-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-022-00610-8</ArticleId><ArticleId IdType="pmc">PMC8916486</ArticleId><ArticleId IdType="pubmed">35277694</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang K., Wei Z., Wu X. Impaired serological response to COVID-19 vaccination following anticancer therapy: A systematic review and meta-analysis. J. Med. Virol. 2022;94:4860&#x2013;4868. doi: 10.1002/jmv.27956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27956</ArticleId><ArticleId IdType="pmc">PMC9349696</ArticleId><ArticleId IdType="pubmed">35750492</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W., Chen C., Tang J., Wang C., Zhou M., Cheng Y., Mao Q. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: A meta-analysis. Ann. Med. 2022;54:516&#x2013;523. doi: 10.1080/07853890.2022.2034936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2034936</ArticleId><ArticleId IdType="pmc">PMC8820829</ArticleId><ArticleId IdType="pubmed">35118917</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang D.T., McCreary E.K., Bariola J.R., Minnier T.E., Wadas R.J., Shovel J.A., Seymour C.W. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial. JAMA Netw. Open. 2022;5:e2220957. doi: 10.1001/jamanetworkopen.2022.20957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.20957</ArticleId><ArticleId IdType="pmc">PMC10881222</ArticleId><ArticleId IdType="pubmed">35834252</ArticleId></ArticleIdList></Reference><Reference><Citation>Amani B., Amani B. Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis. Rev. Med. Virol. 2022;32:e2402. doi: 10.1002/rmv.2402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2402</ArticleId><ArticleId IdType="pmc">PMC9874927</ArticleId><ArticleId IdType="pubmed">36226323</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>